Central nervous system GABAergic pathway

"Central nervous system GABAergic pathway modulation" is not a specific molecule or receptor but rather refers to the modulation of GABAergic (gamma-aminobutyric acid-mediated) neurotransmission in the CNS, encompassing a range of molecular targets such as GABA_A receptors (ion channels), GABA_B receptors (G protein-coupled receptors), GABA transporters, and enzymes involved in GABA synthesis or metabolism[1][2][5]. GABA is the chief inhibitory neurotransmitter in the adult mammalian CNS, where it reduces neuronal excitability and serves critical functions in neurodevelopment, inhibition, and neuroplasticity[1][7]. Drugs and therapeutic strategies targeting the GABAergic pathway are used for conditions such as epilepsy, anxiety, depression, autism spectrum disorder, and neurodegenerative diseases[2][4][6][8]. However, "GABAergic pathway modulation" itself does not designate a single recognized drug target, but rather an entire signaling system with multiple druggable nodes—primarily GABA_A and GABA_B receptors[1][7]. As a result, this entry represents an over-broad or non-canonical target descriptor, and should be mapped to appropriate molecular targets for structured information extraction; most commonly, these would be GABA_A receptor (chloride channel/ion channel) or GABA_B receptor (G protein-coupled receptor), depending on the context and specific pharmacological intervention[1][5].

Other names

GABAergic signaling pathwayGABA neurotransmissionCNS GABAergic system

Positive allosteric modulation of GABA_A receptors; Inhibition of GABA reuptake (GAT inhibition); Direct agonism or antagonism of GABA receptors (GABA_A, GABA_B); Modulation of chloride or potassium channel activity linked to GABA receptor function